☆ 4.6 Article

Ixazomib combined with lenalidomide and dexamethasone chemotherapy for newly diagnosed multiple myeloma in China-Compared with bortezomib/lenalidomide/dexamethasone

CANCER MEDICINE (2023)

Related references

Note: Only part of the references are listed.

Letter Oncology

Outcomes of triple class (proteasome inhibitor, IMiDs and monoclonal antibody) refractory patients with multiple myeloma

Saurabh Zanwar et al.

LEUKEMIA (2022)

Add to Collection

Article Oncology

Ixazomib-based maintenance therapy after bortezomib-based induction in patients with multiple myeloma not undergoing transplantation: A real-world study

Man Shen et al.

Summary: This study retrospectively analyzed the outcome and safety of ixazomib-based maintenance therapy in MM patients who responded well to bortezomib-based induction therapy, showing that ixazomib is an efficacious, tolerable, and convenient option for long-term maintenance therapy. The results confirmed the association between deepening responses with ixazomib and prolonged progression-free survival (PFS).

CANCER MEDICINE (2022)

Add to Collection

Article Cardiac & Cardiovascular Systems

Doxycycline Combined With Bortezomib-Cyclophosphamide-Dexamethasone Chemotherapy for Newly Diagnosed Cardiac Light-Chain Amyloidosis: A Multicenter Randomized Controlled Trial

Kai-Ni Shen et al.

Summary: This study compared the efficacy of combined doxycycline and CyBorD with CyBorD alone in the treatment of cardiac light chain amyloidosis. The results showed that the addition of doxycycline did not significantly prolong progression-free survival or cardiac progression-free survival compared to CyBorD alone.

CIRCULATION (2022)

Add to Collection

Article Oncology

A randomized phase 3 study of ixazomib-dexamethasone versus physician's choice in relapsed or refractory AL amyloidosis

Angela Dispenzieri et al.

Summary: In relapsed/refractory AL amyloidosis patients, there was no significant difference in hematologic response rate and complete response rate between the ixazomib-dexamethasone treatment group and physician's choice treatment group, but patients in the ixazomib-dexamethasone group had a significantly longer median time to vital organ deterioration or mortality.

LEUKEMIA (2022)

Add to Collection

Review Oncology

Targeting CD47 for cancer immunotherapy

Zhongxing Jiang et al.

Summary: Significant progress has been made in targeting CD47 for cancer immunotherapy in solid tumors and hematological malignancies, with a total of 46 clinical trials related to CD47 in the USA and 23 in China. Most of the trials are in early phases, and the new generation CD47 antibodies have shown promising results.

JOURNAL OF HEMATOLOGY & ONCOLOGY (2021)

Add to Collection

Article Oncology

Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

Hyuna Sung et al.

Summary: The global cancer burden in 2020 saw an estimated 19.3 million new cancer cases and almost 10.0 million cancer deaths. Female breast cancer surpassed lung cancer as the most commonly diagnosed cancer, while lung cancer remained the leading cause of cancer death. These trends are expected to rise in 2040, with transitioning countries experiencing a larger increase compared to transitioned countries due to demographic changes and risk factors associated with globalization and a growing economy. Efforts to improve cancer prevention measures and provision of cancer care in transitioning countries will be crucial for global cancer control.

CA-A CANCER JOURNAL FOR CLINICIANS (2021)

Add to Collection

Article Multidisciplinary Sciences

Targeting NSD2-mediated SRC-3 liquid-liquid phase separation sensitizes bortezomib treatment in multiple myeloma

Jing Liu et al.

Summary: High expression of steroid receptor coactivator-3 (SRC-3) is correlated with relapse/refractory and poor outcomes in multiple myeloma (MM) patients treated with bortezomib (BTZ)-based regimens, and overexpression of histone methyltransferase NSD2 may contribute to acquired drug resistance by coordinating and enhancing SRC-3 in MM cells. Targeting SRC-3 or interfering with its interactions with NSD2 using a newly developed inhibitor, SI-2, can sensitize BTZ treatment and overcome drug resistance in MM patients.

NATURE COMMUNICATIONS (2021)

Add to Collection

Review Hematology

Current approaches to management of high-risk multiple myeloma

Sarah Goldman-Mazur et al.

Summary: The median overall survival for multiple myeloma patients is nearly 10 years, but a significant percentage still have poor prognosis. Therefore, individualized and intensive treatment approaches should be utilized, especially for high-risk patients. This includes using effective drug combinations, considering autologous stem cell transplantation, and maintenance based on proteasome inhibitor-based combinations.

AMERICAN JOURNAL OF HEMATOLOGY (2021)

Add to Collection

Article Hematology

Oral ixazomib, lenalidomide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma

Thierry Facon et al.

Summary: Continuous treatment with lenalidomide-dexamethasone (Rd) plus ixazomib showed a progression-free survival benefit compared to placebo in transplant-ineligible newly diagnosed multiple myeloma patients. Addition of ixazomib to Rd led to higher rates of complete and very good partial response, especially in high-risk cytogenetics subgroup. The combination therapy was generally well-tolerated with manageable toxicities and no new safety signals observed.

BLOOD (2021)

Add to Collection

Review Oncology

Novel Molecular Mechanism of Lenalidomide in Myeloid Malignancies Independent of Deletion of Chromosome 5q

Isaac Park et al.

Summary: Lenalidomide and other IMiDs have shown clinical efficacy in certain subtypes of hematologic malignancies, such as multiple myeloma and lower-risk MDS with del(5q). Despite superior clinical response, relapse and resistance are still challenges in IMiD therapy. Recent studies have revealed novel molecular mechanisms of IMiD-based anti-tumor therapy.

CANCERS (2021)

Add to Collection

Review Oncology

Prognostic and predictive biomarker developments in multiple myeloma

Craig T. Wallington-Beddoe et al.

Summary: New approaches are needed to stratify multiple myeloma patients based on prognosis and therapeutic decision-making, however, insufficient information currently exists to utilize biomarkers to tweak treatment. With the increasing complexity of drug classes used to treat multiple myeloma, clinically useful biomarkers are crucial in guiding personalized patient management.

JOURNAL OF HEMATOLOGY & ONCOLOGY (2021)

Add to Collection

Review Immunology

Bortezomib: a proteasome inhibitor for the treatment of autoimmune diseases

Naeemeh Khalesi et al.

Summary: Autoimmune diseases are conditions where the immune system cannot distinguish self from non-self, leading to tissue injury. The proteasome inhibitor bortezomib has shown effectiveness in treating patients with ADs resistant to conventional therapies.

INFLAMMOPHARMACOLOGY (2021)

Add to Collection

Article Oncology

Bortezomib Inhibits Multiple Myeloma Cells by Transactivating ATF3 to Trigger miR-135a-5p-Dependent Apoptosis

Xiaolan Lai et al.

Summary: This study found that ATF3 increased and regulated cell apoptosis in the process of bortezomib treatment, while being negatively regulated by miR-135a-5p. These results reveal the combinatorial regulatory patterns of ATF3 and miR-135a-5p in the regulatory protein interactome, indicating the clinical significance of the miR-135a-5p-ATF3 protein interaction network in bortezomib therapy.

FRONTIERS IN ONCOLOGY (2021)

Add to Collection

Article Medicine, General & Internal

Real-Life Experience With First-Line Therapy Bortezomib Plus Melphalan and Prednisone in Elderly Patients With Newly Diagnosed Multiple Myeloma Ineligible for High Dose Chemotherapy With Autologous Stem-Cell Transplantation

Gabriele Buda et al.

Summary: This study retrospectively analyzed data on 164 newly diagnosed MM patients not eligible for high-dose chemotherapy with autologous stem-cell transplantation, showing that the VMP regimen is highly effective in elderly patients with good overall survival and event-free survival outcomes, with age and gender not being negative predictors of survival.

FRONTIERS IN MEDICINE (2021)

Add to Collection

Review Oncology

Extramedullary disease in multiple myeloma

Radhika Bansal et al.

Summary: Extramedullary multiple myeloma (EMD) is a challenging disease from therapeutic and biological perspectives, with unclear pathogenetic mechanisms. In the era of novel agents, there is a rising incidence of EMD, but lack of standard treatment approaches.

BLOOD CANCER JOURNAL (2021)

Add to Collection

Article Biochemistry & Molecular Biology

Molecular Mechanisms of Bortezomib Action: Novel Evidence for the miRNA-mRNA Interaction Involvement

Karolina Luczkowska et al.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)

Add to Collection

Article Cell Biology

Inhibition of PLK4 might enhance the anti-tumour effect of bortezomib on glioblastoma via PTEN/PI3K/AKT/mTOR signalling pathway

Jing Wang et al.

JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2020)

Add to Collection

Article Oncology

Bortezomib-based consolidation or maintenance therapy for multiple myeloma: a meta-analysis

Shijia Zhang et al.

BLOOD CANCER JOURNAL (2020)

Add to Collection

Article Hematology

Real-world effectiveness and safety of ixazomib-lenalidomide-dexamethasone in relapsed/refractory multiple myeloma

Evangelos Terpos et al.

ANNALS OF HEMATOLOGY (2020)

Add to Collection

Article Biochemistry & Molecular Biology

Iron regulates myeloma cell/macrophage interaction and drives resistance to bortezomib

Giuseppina Camiolo et al.

REDOX BIOLOGY (2020)

Add to Collection

Review Oncology

Non-Hematologic Toxicity of Bortezomib in Multiple Myeloma: The Neuromuscular and Cardiovascular Adverse Effects

Elia Pancheri et al.

CANCERS (2020)

Add to Collection

Review Pharmacology & Pharmacy

Clinical Pharmacology of Ixazomib: The First Oral Proteasome Inhibitor

Neeraj Gupta et al.

CLINICAL PHARMACOKINETICS (2019)

Add to Collection

Article Oncology

Ixazomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma: long-term follow-up including ixazomib maintenance

Shaji K. Kumar et al.

LEUKEMIA (2019)

Add to Collection

Review Pharmacology & Pharmacy

A Practical Review of Proteasome Pharmacology

Tiffany A. Thibaudeau et al.

PHARMACOLOGICAL REVIEWS (2019)

Add to Collection

Article Oncology

All-oral ixazomib, cyclophosphamide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma

Meletios A. Dimopoulos et al.

EUROPEAN JOURNAL OF CANCER (2019)

Add to Collection

Article Hematology

Patient-reported health-related quality of life from the phase III TOURMALINE-MM1 study of ixazomib-lenalidomide-dexamethasone versus placebo-lenalidomide-dexamethasone in relapsed/refractory multiple myeloma

Xavier Leleu et al.

AMERICAN JOURNAL OF HEMATOLOGY (2018)

Add to Collection

Article Hematology

Twice-weekly ixazomib in combination with lenalidomide-dexamethasone in patients with newly diagnosed multiple myeloma

Paul G. Richardson et al.

BRITISH JOURNAL OF HAEMATOLOGY (2018)

Add to Collection

Article Hematology

A pharmacokinetics and safety phase 1/1b study of oral ixazomib in patients with multiple myeloma and severe renal impairment or end-stage renal disease requiring haemodialysis

Neeraj Gupta et al.

BRITISH JOURNAL OF HAEMATOLOGY (2016)

Add to Collection

Article Pharmacology & Pharmacy

Ixazomib: First Global Approval

Matt Shirley

DRUGS (2016)

Add to Collection

Article Cell Biology

Bortezomib induces apoptosis of endometrial cancer cells through microRNA-17-5p by targeting p21

Yuan Shen et al.

CELL BIOLOGY INTERNATIONAL (2013)

Add to Collection

Article Hematology

Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma

Shaji Kumar et al.

BLOOD (2012)

Add to Collection

Article Hematology

Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma

Paul G. Richardson et al.

BLOOD (2010)

Add to Collection

Article Medicine, General & Internal

Bortezomib or high-dose dexamethasone for relapsed multiple myeloma

PG Richardson et al.

NEW ENGLAND JOURNAL OF MEDICINE (2005)

Add to Collection

© Peeref 2019-2024. All rights reserved.